Compare
Aldeyra Therapeutics, Inc. vs Werewolf Therapeutics, Inc. vs Northwest Biotherapeutics Inc vs Scienture Holdings, Inc.
| Latest fiscal year | Aldeyra Therapeutics, Inc. ALDX | Werewolf Therapeutics, Inc. HOWL | Northwest Biotherapeutics Inc NWBO | Scienture Holdings, Inc. SCNX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $1.38M | $431.6K |
| Revenue growth (YoY) | n/a | n/a | -0.3% | +215.9% |
| Gross margin | n/a | n/a | n/a | 76.8% |
| Operating margin | n/a | n/a | n/m | n/m |
| Net margin | n/a | n/a | n/m | n/m |
| Net income | -$33.85M | -$60.82M | -$60.16M | -$41.51M |
| EPS (Diluted) | -$0.56 | -$1.33 | -$0.04 | -$2.70 |
| Operating cash flow | -$33.35M | -$60.29M | -$44.76M | -$13.38M |
| Free cash flow | n/a | -$60.29M | -$46.27M | n/a |
| Cash & equivalents | $70.04M | $57.05M | $3.04M | $6.66M |
| Total assets | $72.06M | $69.40M | $81.29M | $84.18M |
| Total liabilities | $27.81M | $44.59M | $128.86M | $14.06M |
| Shareholders' equity | $44.25M | $24.80M | -$60.28M | $70.12M |
| Return on year-end equity | -76.5% | -245.2% | n/a | -59.2% |
| Shares outstanding | 60.16M | 48.60M | 1.56B | 40.63M |
Revenue, most recent five fiscal years
| Fiscal year | Aldeyra Therapeutics, Inc. | Werewolf Therapeutics, Inc. | Northwest Biotherapeutics Inc | Scienture Holdings, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $1.38M Ended 2025-12-31 | $431.6K Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $1.38M Ended 2024-12-31 | $136.6K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $1.93M Ended 2023-12-31 | $1.36M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $1.68M Ended 2022-12-31 | $10.25M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $1.00M Ended 2021-12-31 | $9.89M Ended 2021-12-31 |